問卷

TPIDB > Search Result > Clinical Trials List

Clinical Trials List

Protocol NumberGLPG0634-CL-336
Active

2022-02-01 - 2026-12-31

Phase III

Recruiting3

ICD-10M08.1

Juvenile ankylosing spondylitis

ICD-10M45.0

Ankylosing spondylitis of multiple sites in spine

ICD-10M45.1

Ankylosing spondylitis of occipito-atlanto-axial region

ICD-10M45.2

Ankylosing spondylitis of cervical region

ICD-10M45.3

Ankylosing spondylitis of cervicothoracic region

ICD-10M45.4

Ankylosing spondylitis of thoracic region

ICD-10M45.5

Ankylosing spondylitis of thoracolumbar region

ICD-10M45.6

Ankylosing spondylitis lumbar region

ICD-10M45.7

Ankylosing spondylitis of lumbosacral region

ICD-10M45.8

Ankylosing spondylitis sacral and sacrococcygeal region

ICD-10M45.9

Ankylosing spondylitis of unspecified sites in spine

ICD-10M48.8X1

Other specified spondylopathies, occipito-atlanto-axial region

ICD-10M48.8X2

Other specified spondylopathies, cervical region

ICD-10M48.8X3

Other specified spondylopathies, cervicothoracic region

ICD-10M48.8X4

Other specified spondylopathies, thoracic region

ICD-10M48.8X5

Other specified spondylopathies, thoracolumbar region

ICD-10M48.8X6

Other specified spondylopathies, lumbar region

ICD-10M48.8X7

Other specified spondylopathies, lumbosacral region

ICD-10M48.8X8

Other specified spondylopathies, sacral and sacrococcygeal region

ICD-10M48.8X9

Other specified spondylopathies, site unspecified

ICD-9720.0

Ankylosing spondylitis

  • Trial Applicant

    IQVIA RDS Taiwan Ltd.

  • Sponsor

  • Trial scale

    Multi-Regional Multi-Center

  • Update

    2026/02/01

Investigators and Locations

Principal Investigator Chi-Ching Chang Division of Rheumatology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator 陳嘉夆 Division of Rheumatology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator 曾瑞成 Division of Rheumatology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Condition/Disease

Objectives

Test Drug

Active Ingredient

Dosage Form

Dosage

Endpoints

Inclution Criteria

The Estimated Number of Participants

  • Taiwan

    25 participants

  • Global

    476 participants